48.45
6.25 (14.81%)
| Penutupan Terdahulu | 42.20 |
| Jumlah Dagangan | 2,829,049 |
| Harga / Pendapatan (P/E Ke hadapan) | 10.55 |
| Harga / Jualan (P/S) | 9.39 |
| Harga / Buku (P/B) | 20.58 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -1,135.42% |
| EPS Cair (TTM) | -1.71 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 5.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 297.04% |
| Nisbah Semasa (MRQ) | 2.93 |
| Aliran Tunai Operasi (OCF TTM) | -99.23 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -64.38 M |
| Pulangan Atas Aset (ROA TTM) | -37.66% |
| Pulangan Atas Ekuiti (ROE TTM) | -203.98% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Liquidia Corporation | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | 0.0 |
| Volatiliti Harga | 2.2 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | -2.5 |
| Persekitaran Makro | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | 0.64 |
|
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 13.64% |
| % Dimiliki oleh Institusi | 65.04% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Findell Capital Management Llc | 30 Jun 2026 | 3,502,112 |
| Caprock Group, Llc | 30 Jun 2026 | 1,409,759 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| ADAIR JASON | - | 43.74 | -688 | -30,093 |
| BOYLE DANA | - | 43.74 | -1,581 | -69,153 |
| Jumlah Keseluruhan Kuantiti Bersih | -2,269 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -99,246 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 43.74 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| ADAIR JASON | Pegawai | 26 Oct 2026 | Jual automatik (-) | 688 | 43.74 | 30,093 |
| BOYLE DANA | Pegawai | 26 Oct 2026 | Jual automatik (-) | 1,581 | 43.74 | 69,153 |
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |